Unknown to 99.999% of investors, indeed.
I recently tried to entice a friend of mine who's a buy-side biotech analyst to look into CTIX (as he had "tipped me off" to CBST back when it was around $10), and he hadn't heard of CTIX. I told him about single dose, no SAEs, no resistance after 30+ serial passages, mimic of human defensin, rapidly bacteriocidal, equivalent to dapto in ABSSSI, the recent 2b topline results, etc... He said his firm wouldn't buy CTIX at this stage due to low market cap, but he could for his personal account, and would definitely look into it.
He talks to biotech and pharma management quite a bit, and sent me a very brief note the other day that some antibiotic company's president told him "there is significant renal toxicity." I was very surprised and pointed him to links showing no such thing in 250+ patients in the two Phase II studies. So either the other antibiotic company's president is wrong out of ignorance (more likely), willfully spreading misinformation (possible?), or somehow correct (highly doubtful).
In any event, just thought I'd share the little story, and note that it seems hard to get institutional investor types to be interested in CTIX at this stage, as I believe there is a lot of unawareness about brilacidin and CTIX still, perhaps because it's such a low market cap OTC stock, that people don't think little David can challenge Goliath. Maybe that's where the little retail investor, like the little nimble biotech able to buy Polymedix's assets for peanuts, has an advantage? or maybe experienced biotech investors wait for a safer thing (less risk with less reward). He did call many of my ideas "lottery pick" type ideas, but I keep holding my tickets closely and swingin' for the fences! Come on Willy Wonka. :)
AI
Market Data 
Markets 
